PharmaShots Weekly Snapshots (September 20 – 24, 2021)
Everest’s SPR206 Receives the NMPA’s IND Approval for the Treatment of MDR Gram-Negative Bacterial Infections Published: Sept 24, 2021 | Tags: Everest, SPR206, NMPA, IND, […]
Everest’s SPR206 Receives the NMPA’s IND Approval for the Treatment of MDR Gram-Negative Bacterial Infections Published: Sept 24, 2021 | Tags: Everest, SPR206, NMPA, IND, […]
Shots: The NMPA has approved the IND application of SPR206 (IV) for the treatment of MDR gram-negative bacterial infections. Everest will initiate the clinical program […]
Shots: Everest to get the rights to develop & commercialize Abs resulting from the collaboration. AbCellera to receive research payments and is eligible to receive […]
Shots: Sinovent & SinoMab to receive $12M up front, ~$549M in development, regulatory & commercial milestone along with royalties on net sales of a product […]
Shots: Providence to receive $100M up front for Providence’s PTX-COVID19-B, mRNA technology & other products, ~$300M upon achievement of milestones, $100M in profit-sharing along with […]
Copyright © 2024 | WordPress Theme by MH Themes